Understanding the relationship between clathrin-mediated endocytosis and transendocytosis of CTLA-4: cell biology at the heart of immune regulation.
Lead Research Organisation:
University College London
Department Name: Immunology and Molecular Pathology
Abstract
We rely on our immune systems to keep us alive in the face of constant challenges from infections. Because we never know what each infection will look like we generate an immune system that contains many millions of different cells each capable of recognising different infections. Whilst this solves the problem of being able to recognise a vast array of different bacteria and viruses, it creates a second problem which is that those same immune cells can now also recognise bits of our bodies causing disease. Controlling our immune system so that it only attacks invaders and not our bodies is critical and getting it wrong can be fatal. Understanding how the immune system achieves this balance is relevant to most areas of our health. Understanding the mechanism underpinning this balance is the basis of this proposal.
To understand this process we need to focus on proteins found at the interface between two types of immune cell, the T cell and the dendritic cell which are responsible for initiating a response. The T cell expresses two proteins, CD28 which acts as a "go" signal and CTLA-4 which inhibits this process. Surprisingly, both CD28 and CTLA-4 interact with the same proteins called CD80 and CD86. We recently discovered that CTLA-4 acts like a tiny hoover and can remove CD80 and CD86 molecules from the surface of dendritic cells using an unusual process called transendocytosis. By hoovering up CD80 and CD86 this means that there is effectively a competition between CD28 and CTLA-4. Removing all the ligands prevents CD28 from receiving a "go" signal keeping our immune system switched off. In this proposal we are seeking to understand exactly how the CTLA-4 hoover functions and by doing this better understand situations where the process goes wrong.
To perform this work we will use several approaches:
1) We will take apart the CTLA-4 protein in order to figure out which bits are necessary for it to work.
2) We will find our which parts of the cell interact with CTLA-4 in order to promote transendocytosis.
3) We will used advanced microscopy to visualise CTLA-4 interacting with its cellular partners to understand the time and place where transendocytosis occurs.
4) We will test our predictions to see whether interfering with selected parts of the CTLA-4 hoover mechanism cause defects in our immune system as we expect.
Together these experiments will provide a complete picture of both an unusual process in biology and a better understanding of how an essential part of our immune system works.
To understand this process we need to focus on proteins found at the interface between two types of immune cell, the T cell and the dendritic cell which are responsible for initiating a response. The T cell expresses two proteins, CD28 which acts as a "go" signal and CTLA-4 which inhibits this process. Surprisingly, both CD28 and CTLA-4 interact with the same proteins called CD80 and CD86. We recently discovered that CTLA-4 acts like a tiny hoover and can remove CD80 and CD86 molecules from the surface of dendritic cells using an unusual process called transendocytosis. By hoovering up CD80 and CD86 this means that there is effectively a competition between CD28 and CTLA-4. Removing all the ligands prevents CD28 from receiving a "go" signal keeping our immune system switched off. In this proposal we are seeking to understand exactly how the CTLA-4 hoover functions and by doing this better understand situations where the process goes wrong.
To perform this work we will use several approaches:
1) We will take apart the CTLA-4 protein in order to figure out which bits are necessary for it to work.
2) We will find our which parts of the cell interact with CTLA-4 in order to promote transendocytosis.
3) We will used advanced microscopy to visualise CTLA-4 interacting with its cellular partners to understand the time and place where transendocytosis occurs.
4) We will test our predictions to see whether interfering with selected parts of the CTLA-4 hoover mechanism cause defects in our immune system as we expect.
Together these experiments will provide a complete picture of both an unusual process in biology and a better understanding of how an essential part of our immune system works.
Technical Summary
The CD28/CTLA-4 pathway controls the key decision point in T cell activation. It is clear from knockout mice that CD28 is critical for generating effective T cell responses, immune memory and for providing T cell help needed for class switched high affinity antibody responses. In contrast, CTLA-4 is an essential inhibitor of T cell responses and its loss causes fatal multi-organ autoimmune destruction. These two opposing receptors are governed via interactions with a pair of ligands, CD80 and CD86, to which both receptors bind. Understanding how CTLA-4 works is fundamental to our understanding of adaptive immunity but is largely incomplete.
We recently identified a novel mechanism of action for CTLA-4 where we observed that it acts as a ligand depleting mechanism, which we term transendocytosis(TE). In this process CTLA-4 utilises its unusual cell biology to capture, internalise and degrade entire trans-membrane ligands expressed on antigen presenting cells. The molecular mechanism underpinning transendocytosis is still unclear. We have also established that there are clear differences in the requirements for CTLA-4 to undergo clathrin-mediated endocytosis (which happens in the absence of its ligands) compared with TE. Here we propose to carry out experiments to understand the differences between clathrin-mediated endocytosis and TE of CTLA-4 in order to better define the nature of TE and the pathways affecting this process. We will carry out mutagenesis of CTLA-4 to define regions that are required for TE as well as using a variety of knockdown and dominant interfering mutants to establish the cellular pathways involved. We will apply high resolution imaging technologies to define the spatial and structural organisation of components of the TE pathways and finally, we will test the significance of the molecular interactions identified via these approaches for their impact on immune function.
We recently identified a novel mechanism of action for CTLA-4 where we observed that it acts as a ligand depleting mechanism, which we term transendocytosis(TE). In this process CTLA-4 utilises its unusual cell biology to capture, internalise and degrade entire trans-membrane ligands expressed on antigen presenting cells. The molecular mechanism underpinning transendocytosis is still unclear. We have also established that there are clear differences in the requirements for CTLA-4 to undergo clathrin-mediated endocytosis (which happens in the absence of its ligands) compared with TE. Here we propose to carry out experiments to understand the differences between clathrin-mediated endocytosis and TE of CTLA-4 in order to better define the nature of TE and the pathways affecting this process. We will carry out mutagenesis of CTLA-4 to define regions that are required for TE as well as using a variety of knockdown and dominant interfering mutants to establish the cellular pathways involved. We will apply high resolution imaging technologies to define the spatial and structural organisation of components of the TE pathways and finally, we will test the significance of the molecular interactions identified via these approaches for their impact on immune function.
Planned Impact
As detailed above there will be wide ranging benefit to academia at an international level as we gain a greater understanding of this important pathway. Accordingly, this work will directly contribute to the knowledge economy by providing new insights which will impact at the level of academic research but also at graduate level immunology. For example, our BBSRC funded work identifying CTLA-4 TE as a ligand removal mechanism now appears in graduate texts such as Cellular and Molecular Immunology by Abbas. This work provides a new immunological paradigm and is therefore capable of influencing the thinking of new generations of immunologists.
In addition, there is very significant potential for the work to impact on the the pharmaceutical industry. There are currently a number of companies who have active development programmes based in this area of work which target cancer, autoimmunity, transplantation. The knowledge gained from our studies can be readily translated into new approaches for drug development. Given the large number of immunologically related areas affected by this area of work there is enormous potential for significant economic impact.The long term outcome of this work will therefore be in the potential for better drugs and vaccines with greater efficacy and fewer side effects.
Given our leading position in the study of trans-endocytosis as a process, there is also significant potential for developing technological advances in methods of studying this immune process which may have impact on areas of cell biology outside of immunology. This work will therefore build research capacity and contribute to training of individuals in this emerging field.
Ultimately, the sophisticated knowledge gained from enhanced understanding of the CD28 /CTLA-4 pathways has the potential to impact on individuals with immunological diseases and groups who support them. Despite the basic nature of the work in this proposal the fundamental understanding gained from our approach is already being applied in the context of immunological disorders. Based on our expertise, our lab is able to provide support for the clinical immunology laboratory at the Royal Free in terms of measuring CTLA-4 function. Arguably, our lab is one of very few worldwide with the tools (generated with BBSRC support) capable of measuring CTLA-4 behaviour and its role in Treg function and this is now identifying defects in patients with immune deficiency and autoimmunity. Strikingly, and of relevance to this proposal, it is emerging that defects in pathways relating to intracellular protein trafficking also affect CTLA-4 function and are likely disease causative. This provides a clear example of an immediate impact on health generated entirely from BBSRC sponsored studies on basic mechanisms of immune regulation
Together the above demonstrates the potential for significant impacts of this research area on lifelong health and wellbeing.
In addition, there is very significant potential for the work to impact on the the pharmaceutical industry. There are currently a number of companies who have active development programmes based in this area of work which target cancer, autoimmunity, transplantation. The knowledge gained from our studies can be readily translated into new approaches for drug development. Given the large number of immunologically related areas affected by this area of work there is enormous potential for significant economic impact.The long term outcome of this work will therefore be in the potential for better drugs and vaccines with greater efficacy and fewer side effects.
Given our leading position in the study of trans-endocytosis as a process, there is also significant potential for developing technological advances in methods of studying this immune process which may have impact on areas of cell biology outside of immunology. This work will therefore build research capacity and contribute to training of individuals in this emerging field.
Ultimately, the sophisticated knowledge gained from enhanced understanding of the CD28 /CTLA-4 pathways has the potential to impact on individuals with immunological diseases and groups who support them. Despite the basic nature of the work in this proposal the fundamental understanding gained from our approach is already being applied in the context of immunological disorders. Based on our expertise, our lab is able to provide support for the clinical immunology laboratory at the Royal Free in terms of measuring CTLA-4 function. Arguably, our lab is one of very few worldwide with the tools (generated with BBSRC support) capable of measuring CTLA-4 behaviour and its role in Treg function and this is now identifying defects in patients with immune deficiency and autoimmunity. Strikingly, and of relevance to this proposal, it is emerging that defects in pathways relating to intracellular protein trafficking also affect CTLA-4 function and are likely disease causative. This provides a clear example of an immediate impact on health generated entirely from BBSRC sponsored studies on basic mechanisms of immune regulation
Together the above demonstrates the potential for significant impacts of this research area on lifelong health and wellbeing.
Organisations
Publications
Douthwaite J
(2017)
A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.
in Journal of immunology (Baltimore, Md. : 1950)
Halliday N
(2020)
CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T Cell Homeostasis in the Presence of High Levels of CTLA-4.
in Frontiers in immunology
Janman D
(2021)
Regulation of CTLA-4 recycling by LRBA and Rab11.
in Immunology
Kennedy A
(2022)
Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation.
in Nature immunology
Khailaie S
(2018)
Characterization of CTLA4 Trafficking and Implications for Its Function.
in Biophysical journal
Liaskou E
(2017)
Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals.
in Scientific reports
Rowshanravan B
(2018)
CTLA-4: a moving target in immunotherapy.
in Blood
Soskic B
(2020)
CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis.
in Frontiers in immunology
Description | The CTLA-4 pathway controls key aspects of our immune response. Individuals with deficiency in CTLA-4 suffer from autoimmune conditions affecting a range of organs. In addition a new generation of cancer therapies have been pioneered by manipulating the CTLA-4 pathway. Nonetheless our understanding of exactly how CTLA-4 functions is incomplete. Work funded by the BBSRC has enabled us to identify a mechanism of action for CTLA-4 which we call transendocytosis. In this project we have made further progress in understanding the transendocytosis mechanism. In particular we have begun to understand what happens once CTLA-4 engages with its two ligands and how this affects its function. we have found that the two ligands modify CTLA-4 differently. Our understanding of CTLA-4 cell biology has helped us to design tests to study CTLA-4 clinically and design new strategies to manipulate the CTLA-4 pathway. Findings based on some of this work are now submitted for publication. |
Exploitation Route | We plan to continue working on the mechanism of CTLA-4 action and have several papers reporting our findings under development. we are also in discussions with pharmaceutical companies on ways to manipulate CTLA-4 based on our knowledge. It is likely that in the future this work will underpin clinal diagnostic tests for CTLA-4 function. In addition this work may well lead to development of new ways of manipulating the CTLA-4 pathway. |
Sectors | Healthcare,Pharmaceuticals and Medical Biotechnology |
Description | we have provided reagents and know-how to further develop measurements of CTLA-4 into clinical tests of CTLA-4 deficiency. This is being developed in collaboration with Great Ormond St Hospital Our knowledge has enabled us to generate a industrial CASE studentship with Astra Zeneca and emerging partnerships with Pharma companies |
First Year Of Impact | 2020 |
Sector | Healthcare,Pharmaceuticals and Medical Biotechnology |
Description | Talk at European Society For Immune Deficiency meeting (Edinburgh) |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | The biology and understanding we have described has led to the design and implementation of new tests, which inform clinical diagnosis. We are currently discussing how to transfer these to an approved clinical diagnostic setting. presentations such as those above inform the wider clinical audience of such developments. |
Description | Wellcome Trust Investigator award |
Amount | £1,600,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2017 |
End | 03/2022 |
Title | Ligand uptake assays/ CTLA-4 activity measurement |
Description | We have devised assays to look at the level of ligand taken up by CTLA-4 via clathrin mediated endocytosis. This can be normalised to the total amount of CTLA-4 available and is useful for assessing CTLA-4 efficiency. |
Type Of Material | Technology assay or reagent |
Year Produced | 2017 |
Provided To Others? | Yes |
Impact | We have published this method and are establishing its utility in the disease setting. We have now handed this technology and associated CTLA-4 measurements to Great Ormond St Hospital for clinical development. |
Description | Institute Science Open Day |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | Local 6th form school children attended the Institute open day and took part in hands on displays and discussed presentations of our work in small groups. we presented videos microcopy from our work and discussed our findings. we we able to answer questions about our work, how it helps people with disease, careers in science etc. |
Year(s) Of Engagement Activity | 2017 |